Corporate Banner
Satellite Banner
Scientific Communities
Become a Member | Sign in
Home>News>This Article

Novasep Appoints Fine Chemicals Market Director

Published: Thursday, June 06, 2013
Last Updated: Thursday, June 06, 2013
Bookmark and Share
Company strengthens its position by appointing Udo Steinhauer.

Novasep has announced that it has strengthened its position in the fine chemicals marketplace with the appointment of Udo Steinhauer as fine chemicals market director within the synthesis business unit of Novasep.

Udo Steinhauer has a strong industrial experience gained over 18 years in diverse managerial positions.

At Novasep, he will initially focus on four key business areas for Novasep: electronic, cosmetic, flavor and fragrance, and the polymer and biopolymer industry.

“The need for new organic synthesis and purification routes is now critical in the development of the specialty chemicals market,” said Udo Steinhauer.

Steinhauer continued, “As an example, the demand for new organic electronic chemicals in ultrapure quality is continuing to increase. Impurities in cosmetic active ingredients then have to be removed in order to avoid side effects. Another example is in the polymer industry. New additives are required to fulfill the demands of performance plastics and polymers obtained from new synthesis or purification routes of bio-based building blocks. I wanted to join Novasep, with its strong expertise and extended capabilities in organic synthesis and advanced purification, because it is an established player in these markets. It is able to offer a cost-effective response to these increasingly demanding manufacturing challenges.”

“Udo’s appointment is the next significant step in formalizing and developing Novasep’s position in these fine chemical markets,” said Michel Blanc, VP sales and business development of Novasep’s Synthesis Business Unit.

Blanc continued, “These industries require more and more skills in combining smart synthesis with high efficiency purification to develop innovative molecules.”

Novasep offers contract manufacturing solutions using an unparalleled array of specialized techniques that very few companies can handle at one time. This includes hazardous chemistry and large scale chromatography.

The technologies developed by Novasep often allow shorter synthetic pathways and therefore enable significant reduction of costs, time to market and environmental impact.

Novasep’s range of advanced purification techniques include membrane filtration, large scale HPLC, SMB and Varicol® continuous chromatography with integrated solvent recycling capabilities to drastically reduce operating costs.

The main reactions mastered at Novasep at industrial scale include oxidation, azides, nitration, the use of hydrazine, Grignards, alkyllithium, lithium aluminum hydride, carbon disulfide, nitroalkanes and carbonylation reactions.

By outsourcing with Novasep, clients can benefit from Novasep’s 140 years of experience in handling energetic and hazardous chemistry, thereby reducing risk and avoiding CAPEX.

The company offers a full range of integrated services including process development, scale-up and manufacturing from kilogram scale to 1,000’s of tons per year.

In addition to custom manufacturing services, Novasep also provides building blocks, intermediates and specialized reagents.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More Than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Novasep Strengthens its Advisory Board
Professors Alois Fürstner and Alois Jungbauer, renowned experts in catalysis and purification processes, will help boost innovation at Novasep
Tuesday, September 29, 2015
Novasep Invests €10M to Reinforce its Bioconjugation Services
Expansion marks the company’s readiness for full range Antibody Drug Conjugates CMO services.
Thursday, June 25, 2015
Novasep Further Strengthens Management Team
Pierre-Louis Mikus joins as chief legal officer and Bertrand Waymel is promoted to group human resources director.
Wednesday, May 06, 2015
Novasep and Celladon Execute MYDICAR API Supply Agreement
An innovative, genetically-targeted enzyme replacement therapy based on AAV1/SERCA2a.
Thursday, March 26, 2015
Novasep & Celladon Partner
Novasep has entered into an agreement with Celladon, to commercially biomanufacture Celladon’s Mydicar API.
Tuesday, February 24, 2015
Novasep Enters into an Agreement with Celladon
Company selected to commercially biomanufacture Celladon's Mydicar API.
Thursday, February 19, 2015
Novasep Opens New Office in Thailand
Novasep’s extended presence in South East Asia strengthens the company’s ability to address growing needs in the region’s food and feed markets.
Saturday, December 27, 2014
Novasep to Sell its Bahamian Plant to Local Investor
Company has completed the sale of the Bahamian facility and related business of its fully-owned subsidiary, Pharmachem.
Thursday, October 09, 2014
Novasep Passes FDA Inspections on Two Sites
Novasep wins approval to produce new molecular entity for US market.
Thursday, July 24, 2014
Novasep’s €4 M ADC Manufacturing Plant Extension Commissioned
The new Highly Potent API manufacturing capacity at the Le Mans facility will boost Novasep’s ability to meet customer demand for producing anti-cancer therapies.
Friday, May 16, 2014
Novasep Reports Full Year 2013 Results
Results show strong growth and beating guidance.
Friday, March 28, 2014
Novasep Appoints CEO Michel Spagnol as Chairman
Novasep presents strategic developments.
Wednesday, March 05, 2014
Novasep Expands and Opens Subsidiary in India
Subsidiary to meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Friday, February 14, 2014
Novasep Attracts Top Talent to Complete its Executive Team
Thierry Van Nieuwenhove, a seasoned CMO top executive, joins Novasep as president of the Synthesis Business Unit.
Monday, January 20, 2014
Novasep Expands and Opens Subsidiary in India
Novasep Process Engineering Services PVT LTD will meet India’s increasing need for high efficacy processes for its fast growing food and feed industries.
Monday, December 16, 2013
Scientific News
High Throughput Mass Spectrometry-Based Screening Assay Trends
Dr John Comley provides an insight into HT MS-based screening with a focus on future user requirements and preferences.
Revolutionary Technologies Developed to Improve Outcomes for Lung Cancer Patients
Breath test to detect lung cancer brings oxygen directly to the wound.
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Dementia Linked to Deficient DNA Repair
Mutant forms of breast cancer factor 1 (BRCA1) are associated with breast and ovarian cancers but according to new findings, in the brain the normal BRCA1 gene product may also be linked to Alzheimer’s disease.
Using Drug-Susceptible Parasites to Fight Drug Resistance
Researchers at the University of Georgia have developed a model for evaluating a potential new strategy in the fight against drug-resistant diseases.
Boosting Breast Cancer Treatment
To more efficiently treat breast cancer, scientists have been researching molecules that selectively bind to cancer cells and deliver a substance that can kill the tumor cells, for several years.
New Gene Map Reveals Cancer’s Achilles’ Heel
Team of researchers switches off almost 18,000 genes
New Discovery Sheds Light on Disease Risk
Gaps between genes interact to influence the risk of acquiring disease.
How Cells ‘Climb’ to Build Fruit Fly Tracheas
Mipp1 protein helps cells sprout “fingers” for gripping.
Research Finding Could Lead to Targeted Therapies for IBD
Findings published online in Cell Reports.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos